# US 2024/0200003 A1 · Devices and methods for in vitro modeling of metastatic cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0200003 A1
- Document ID: US20240200003A1
- Status: Published application
- Kind: A1
- Application number: 17/997,829
- Filed: 2021-05-05
- Published: 2024-06-20
- Earliest claimed: 2020-05-05
- Assignees: Xylyx Bio, Inc.
- Applicants: Xylyx Bio, Inc.
- Inventors: John O'NEILL; Igal GERMANGUZ; Evelyn ARANDA; Jennifer XIONG; Natalia KISSEL; Alexandra NICHOLS; Drew DALY
- Web page: https://patentgrep.com/patent/US20240200003A1

## CPC

- C12M 21/08: {for producing artificial tissue or for ex-vivo cultivation of tissue (prostheses A61F2/00, grafts A61L27/00)}
- C12N 5/0068: {General culture methods using substrates (for specific animal cell type C12N5/06)}
- C12M 23/16: {Microfluidic devices; Capillary tubes (integrated microfluidic structures B01L3/5027; microreactors B01J19/0093)}
- C12N 5/0693: {Tumour cells; Cancer cells}
- G01N 33/5082: {Supracellular entities, e.g. tissue, organisms}
- G01N 33/5091: {for testing the pathological state of an organism}
- C12N 2501/727: Kinases (EC 2.7.)
- C12N 2501/999: Small molecules not provided for elsewhere
- C12N 2502/14: hepatocytes
- C12N 2502/27: Lung cells, respiratory tract cells
- C12N 2513/00: 3D culture
- C12N 2533/90: Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
- C12M: APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; {APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS}
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

A cell culture platform for modeling metastatic cancer is disclosed. The platform comprises one or more cell culture vessels comprising a plurality of compartments. Each compartment houses a substrate include a decellularized tissue-specific extracellular matrix derived from tissue of a different anatomical region. Each tissue-specific extracellular matrix comprises a homogenous mixture of macromolecule fragments including collagen, elastin, and glycosaminoglycan. A kit for culturing cells in biomimetic environments is also disclosed. The kit comprises a plurality of substrate precursors and at least one reagent. Each substrate precursor comprises a decellularized tissue-specific extracellular matrix derived from tissue of a different anatomical region. The tissue-specific extracellular matrix comprises a homogenous mixture of macromolecule fragments including collagen, elastin, and glycosaminoglycan. The reagent is configured to configured to convert each substrate precursor into a substrate adapted for culturing cells thereon. Methods of assessing a tumor-associated response of a cancer colony are also disclosed herein.

## Claims

### Claim 1

A cell culture platform for modeling metastatic cancer comprising:
one or more cell culture vessels comprising a plurality of compartments, each compartment housing a substrate adapted for culturing cells thereon, wherein each substrate comprises a decellularized tissue-specific extracellular matrix derived from tissue of a different anatomical region,
wherein each tissue-specific extracellular matrix comprises a homogenous mixture of macromolecule fragments including collagen, elastin, and glycosaminoglycan.

### Claim 2 (depends on 1)

The cell culture platform of claim 1, wherein the tissue-specific extracellular matrix derived from tissue of a different anatomical region of each substrate is selected from the group consisting of bone-specific extracellular matrix, liver-specific extracellular matrix, lung-specific extracellular matrix, brain-specific extracellular matrix, kidney-specific extracellular matrix, skin-specific extracellular matrix, intestine-specific extracellular matrix, heart-specific extracellular matrix, and lymph-specific extracellular matrix.

### Claim 3 (depends on 1)

The cell culture platform of claim 1, wherein the plurality of compartments of the one or more cell culture vessels comprise:
a first compartment housing a first substrate;
a compartment housing a second substrate; and
a third compartment housing a third substrate.

### Claim 4 (depends on 3)

The cell culture platform of claim 3, wherein:
the first substrate comprises bone-specific extracellular matrix derived from bone tissue;
the second substrate comprises lung-specific extracellular matrix derived from lung tissue; and
the third substrate comprises liver-specific extracellular matrix derived from liver tissue.

### Claim 5 (depends on 4)

The cell culture platform of claim 4, wherein the first substrate comprises collagen in a concentration of about 580 to about 620 μg/mL, elastin in a concentration of about 40 μg/mL to 50 μg/mL, and glycosaminoglycan in a concentration of about 10 μg/mL to about 20 μg/mL.

### Claim 6 (depends on 4)

The cell culture platform of claim 4, wherein the second substrate comprises collagen in a concentration of about 400 μg/mL to about 530 μg/mL, elastin in a concentration of about 40 μg/mL to 50 μg/mL, and glycosaminoglycan in a concentration of about 3 μg/mL to about 5 μg/mL.

### Claim 7 (depends on 4)

The cell culture platform of claim 4, wherein the third substrate comprises collagen in a concentration of about 1100 μg/mL to about 1300 μg/mL, elastin in a concentration of about 120 μg/mL to 150 μg/mL, and glycosaminoglycan in a concentration of about 5 μg/mL to about 15 μg/mL.

### Claim 8 (depends on 4)

The cell culture platform of claim 4, wherein:
the first substrate has an elastic modulus of about 6 kPa to about 25 kPa;
the second substrate has an elastic modulus of about 2 kPa to about 12 kPa; and
the third substrate has an elastic modulus of about 2 to about 15 kPa.

### Claim 9 (depends on 8)

The cell culture platform of claim 8, wherein:
the first substrate has an elastic modulus of about 6.6 kPa;
the second substrate has an elastic modulus of about 3.1 kPa; and
the third substrate has an elastic modulus of about 2.8 kPa.

### Claim 10 (depends on 1)

The cell culture platform of claim 1, wherein, each tissue-specific extracellular matrix is derived from non-metastatic tissue.

### Claim 11 (depends on 1)

The cell culture platform of claim 1, wherein each tissue-specific extracellular matrix is derived from fibrotic tissue.

### Claim at position 12

-15. (canceled)

### Claim 16 (depends on 1)

The cell culture platform of claim 1, wherein:
the one or more cell culture vessels comprise at least one microfluidic chip;
the plurality of compartments comprise a plurality of microfluidic chambers on the at least one microfluidic chip; and
the one or more fluidic channels comprise one or more microfluidic channels fluidly communicating with the plurality of microfluidic chambers.

### Claim 17

(canceled)

### Claim 18 (depends on 1)

The cell culture platform of claim 1, wherein each substrate is individually selected from the group consisting of a surface coating, a hydrogel, a printable bio-ink, one or more fibers, and a media supplement.

### Claim at position 16

-47. (canceled)

### Claim 48

A method of assessing a response of one or more cancer colonies to a drug, the method comprising:
providing one or more cell culture vessels comprising a plurality of substrates arranged in a compartmentalized manner, each substrate comprising a decellularized tissue-specific extracellular matrix derived from tissue of a different anatomical region;
culturing cancer cells to form a cancer colony on each substrate, wherein the cancer cells are foreign to the tissue-specific extracellular matrix of at least one of the plurality of substrates, thereby forming at least one metastatic cancer colony;
contacting each cancer colony with a drug; and
assessing the response by each cancer colony to the drug.

### Claim at position 18

-52. (canceled)

### Claim 53 (depends on 48)

The method of claim 48, wherein the cancer cells are selected from the group consisting of breast cancer cells and lung cancer cells.

### Claim 54 (depends on 48)

The method of claim 48, wherein the tissue-specific extracellular matrix derived from tissue of a different anatomical region of each substrate is selected from the group consisting of bone-specific extracellular matrix, liver-specific extracellular matrix, lung-specific extracellular matrix, brain-specific extracellular matrix, kidney-specific extracellular matrix, skin-specific extracellular matrix, intestine-specific extracellular matrix, heart-specific extracellular matrix, and lymph-specific extracellular matrix.

### Claim 55 (depends on 48)

The method of claim 48, where the tissue-specific extracellular matrix of each substrate comprises a homogenous mixture of macromolecule fragments including collagen, elastin, and glycosaminoglycan.

### Claim 56

(canceled)

### Claim 57 (depends on 48)

The method of claim 48, wherein each tissue-specific extracellular matrix is derived from fibrotic tissue.

### Claim at position 24

-60. (canceled)

### Claim 61 (depends on 48)

The method of claim 48, wherein each substrate is individually selected from the group consisting of a surface coating, a hydrogel, a printable bio-ink, one or more fibers, and a media supplement.

### Claim 62

A method of assessing cell migration of a primary cancer colony, the method comprising:
providing one or more cell culture vessels comprising:
a first substrate in a first compartment of the one or more cell culture vessels,
one or more second substrates in one or more second compartments of the one or more cell culture vessels,
wherein the first substrate and the one or more second substrates each comprise a decellularized tissue-specific extracellular matrix derived from tissue of a different anatomical region,
wherein the first substrate and the one or more second substrates are arranged in a compartmentalized manner and in fluid communication through one or more fluidic channels;
culturing cancer cells on the first substrate, wherein the cancer cells are native to the tissue-specific extracellular matrix of the first substrate, thereby forming the primary cancer colony,
wherein the one or more fluidic channels are configured to permit cell migration from the first substrate to the one or more second substrates, wherein the cancer cells are adapted to form one or more metastatic cancer colonies on the one or more second substrates; and
assessing the cell migration of the primary cancer colony from the first substrate to the one or more second substrates.

### Claim at position 27

-73. (canceled)
